KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Short-term Investments: 2012-2017

Historic Short-term Investments for Idexx Laboratories (IDXX) over the last 5 years, with Dec 2017 value amounting to $284.3 million.

  • Idexx Laboratories' Short-term Investments rose 19.96% to $284.3 million in Q4 2017 from the same period last year, while for Dec 2017 it was $284.3 million, marking a year-over-year increase of 19.96%. This contributed to the annual value of $284.3 million for FY2017, which is 19.96% up from last year.
  • Latest data reveals that Idexx Laboratories reported Short-term Investments of $284.3 million as of Q4 2017, which was down 0.29% from $285.1 million recorded in Q3 2017.
  • Over the past 5 years, Idexx Laboratories' Short-term Investments peaked at $285.1 million during Q3 2017, and registered a low of $453,000 during Q1 2014.
  • Its 3-year average for Short-term Investments is $227.8 million, with a median of $233.0 million in 2016.
  • In the last 5 years, Idexx Laboratories' Short-term Investments plummeted by 90.07% in 2014 and then skyrocketed by 30,631.79% in 2015.
  • Over the past 5 years, Idexx Laboratories' Short-term Investments (Quarterly) stood at $1.1 million in 2013, then soared by 910.47% to $10.9 million in 2014, then soared by 1,859.01% to $213.6 million in 2015, then rose by 10.94% to $236.9 million in 2016, then rose by 19.96% to $284.3 million in 2017.
  • Its last three reported values are $284.3 million in Q4 2017, $285.1 million for Q3 2017, and $256.9 million during Q2 2017.